Evidence map›Paper›PMID 36498864›Full record

ReviewInternational journal of molecular sciences2022

Triazavirin-A Novel Effective Antiviral Drug.

Oleg N Chupakhin, Vladimir L Rusinov, Mikhail V Varaksin, Evgeny N Ulomskiy, Konstantin V Savateev, Ilya I Butorin, Weijie Du, Zhiyong Sun, Valery N Charushin

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Oleg N ChupakhinDepartment of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, 620002 Ekaterinburg, Russia.
Vladimir L RusinovDepartment of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, 620002 Ekaterinburg, Russia.
Mikhail V VaraksinDepartment of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, 620002 Ekaterinburg, Russia.ORCID 0000-0002-7997-3686
Evgeny N UlomskiyDepartment of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, 620002 Ekaterinburg, Russia.
Konstantin V SavateevDepartment of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, 620002 Ekaterinburg, Russia.ORCID 0000-0001-6040-5155
Ilya I ButorinDepartment of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, 620002 Ekaterinburg, Russia.
Weijie DuDepartment of Pharmacology, The Key Laboratory of Cardiovascular Research, Ministry of Education, College of Pharmacy, Harbin Medical University, Harbin 150086, China.
Zhiyong SunDepartment of Pharmacology, The Key Laboratory of Cardiovascular Research, Ministry of Education, College of Pharmacy, Harbin Medical University, Harbin 150086, China.
Valery N CharushinDepartment of Organic and Biomolecular Chemistry, Institute of Chemical Engineering, Ural Federal University, 620002 Ekaterinburg, Russia.ORCID 0000-0002-9140-358X
Ural Federal University · RUHarbin Medical University · CN

Funding

Ministry of Science and Higher Education of the Russian Federation FEUZ-2022-0001National Natural Science Foundation of China 82161148007Russian Foundation for Basic Research 20-53-55003
6 · The paper itself

Abstract

This review outlines the data of numerous studies relating to the broad-spectrum antiviral drug Triazavirin that was launched on the Russian pharmaceutical market in 2014 as an anti-influenza drug (the international non-patented name is Riamilovir). The range of antiviral activity of Triazavirin has been significantly expanded during recent years; in particular, it has been shown that Triazavirin exhibits activity against tick-borne encephalitis, Rift Valley fever, West Nile fever, and other infections of viral etiology. This drug has been approved for treatment of influenza and acute respiratory infections by the Russian Ministry of Health on the basis of comprehensive clinical trials involving over 450 patients. Triazavirin was found to be a highly effective and well-tolerated drug, allowing its over-the-counter sale. The recently published data on the use of Triazavirin in clinical practice for the treatment of patients with COVID-19 are discussed, with special attention paid to potential biological targets for this drug.

Indexed as

COVID-19Encephalitis, Tick-BorneInfluenza, HumanAnimalsAntiviral AgentsAzolesHumansAntiviral AgentsAzolesantiviral therapyCOVID-19riamilovirSARS-CoV-2triazavirin

Identifiers

PMID36498864
PMCPMC9738222
OpenAlexW4309683860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.